29397 Agoura Road, Suite 107
14 articles with Oncotelic Inc.
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology and COVID-19, reported that PulmoHealTM/ ArtiVedaTM has proven active against mild and moderate COVID-19 following the preplanned prospective analysis of ARTI-19 clinical trial.
Oncotelic Therapeutics, Inc. and COVID-19 and Golden Mountain Partners, ( “ GMP ” ) announced that they are forming a joint venture ( “JV” ) to advance clinical development of Oncotelic’s pharmaceutical pipeline and build out of manufacturing facilities for the commercial launch of Oncotelic’s drug candidates.
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology, infectious diseases and respiratory health announced that, as of June 11, 2021, Oncotelic has discontinued enrollment in its OT-101 clinical trial in patients with COVID-19.
Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundation to provide COVID-19 relief for India, including medicines and oxygen concentrators.
ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") (OTCQB:O TLC) , a leading developer of TGF-β therapeutics for oncology and COVID-19, reports positive top line data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal ™ against COVID-19 in India.
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Chopra Foundation and Jiva are collaborating to bring a webinar regarding new approaches for managing COVID-19 cases as cases spike and new variants arise. The webinar-
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
Also published was a peer-reviewed research article in the prestigious oncology journal Cancers.
New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
The article is titled “In silico Molecular Target Validation Demonstrates Transforming Growth Factor Beta 2 is Strongly Expressed in Pediatric Diffuse Intrinsic Pontine Glioma and Glioblastoma Multiforme"
WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary of Mateon Therapeutics Inc., to provide OT-101 to patients who cannot take part in research trials of the investigational product.
Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue
Oncotelic And Autotelic Announce Clinical Data Supporting IL-8 Spike As A Prognostic Biomarker For Immunotherapy